drugset / Trial / NCT06410248
Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma
Phase 1
Recruiting
30 enrolled
Northwestern University
BrainUp Inc · collabNational Cancer Institute (NCI) · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Triapine inhibits an enzyme responsible for producing molecules required for the production of deoxyribonucleic acid (DNA), which may inhibit tumor cell growth. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving triapine in combination with temozolomide may be safe, tolerable, and/or effective in treating patients with recurrent glioblastoma.
Timeline
- Start
- 2024-07-23
- Primary completion
- 2029-05-12
- Completion
- 2030-05-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Temozolomide | Small molecule | — | Oral |
| Subject | Triapine | Small molecule | — | Oral |